- Pieris Pharmaceuticals is developing a novel class of biological compounds called anticalins.
- The company recently uplisted to the Nasdaq Capital Market and subsequently raised $22.7 million.
- The lead compound, PRS-080, is currently being tested in a Phase 1 trial with data expected in the second half of 2015.
- We think the shares are worth $6 today, which should be realized as the potential for the anticalin technology becomes more fully appreciated.
Please read the article on Seeking-Alpha: LINK